Nintedanib treatment for bleomycin-induced lung injury - First report
Although the antineoplastic agent bleomycin is known for more than 50 years, its exact pharmacological and side-effect mechanisms remain incompletely understood. The major limitation of bleomycin therapy is the risk of pulmonary toxicity which can be diverse, and potentially fatal in 10% of patients...
Shranjeno v:
| Principais autores: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2023-01-01
|
| Serija: | Respiratory Medicine Case Reports |
| Teme: | |
| Online dostop: | http://www.sciencedirect.com/science/article/pii/S2213007123001168 |
| Oznake: |
Brez oznak, prvi označite!
|